XML 43 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Employee Benefit Plans (Tables)
12 Months Ended
Dec. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocated Employee Stock-Based Compensation Expense
We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):
 
Year Ended December 31,
 
202220212020
Research and development$45,350 $46,654 $37,198 
Selling, general and administrative62,224 73,166 67,872 
Total stock-based compensation expense$107,574 $119,820 $105,070 
 
Year Ended December 31,
 
202220212020
Stock options$12,790 $19,048 $19,863 
Restricted stock units69,775 53,629 35,675 
Performance stock units21,616 43,428 47,106 
ESPP3,393 3,715 2,426 
Total stock-based compensation expense$107,574 $119,820 $105,070 
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:
 
Year Ended December 31,
 
202220212020
Stock options$8.36 $9.04 $9.44 
ESPP$5.80 $6.12 $6.12 
Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values
The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:
 
Year Ended December 31,
 
202220212020
Stock options:
Risk-free interest rate2.35 %0.74 %0.30 %
Dividend yield— %— %— %
Volatility48 %51 %54 %
Expected life4.6 years4.6 years4.4 years
ESPP:
Risk-free interest rate1.49 %0.08 %0.79 %
Dividend yield— %— %— %
Volatility45 %47 %52 %
Expected life6 months6 months6 months
Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values
The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:
 
Year Ended December 31,
 
202220212020
Stock options:
Risk-free interest rate2.35 %0.74 %0.30 %
Dividend yield— %— %— %
Volatility48 %51 %54 %
Expected life4.6 years4.6 years4.4 years
ESPP:
Risk-free interest rate1.49 %0.08 %0.79 %
Dividend yield— %— %— %
Volatility45 %47 %52 %
Expected life6 months6 months6 months
Schedule of All Stock Option Activity
Activity for stock options during the year ended December 31, 2022 was as follows (in thousands, except per share amounts):
Shares
Weighted 
Average
Exercise Price
Weighted 
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value
Stock options outstanding at December 31, 2021
13,671 $16.79 
Granted589 $19.99 
Exercised(2,743)$5.74 
Cancelled(635)$21.29 
Stock options outstanding at December 31, 2022
10,882 $19.49 3.0 years$9,377 
Stock options exercisable at December 31, 2022
8,743 $19.17 2.4 years$9,373 
Schedule of All RSU Activity Activity for RSUs during the year ended December 31, 2022 was as follows (in thousands, except per share amounts):
Shares
Weighted 
Average
Grant Date
Fair Value
Weighted 
Average
Remaining
Contractual 
Term
Aggregate
Intrinsic
Value
RSUs outstanding at December 31, 2021
6,828 $21.58 
Awarded7,933 $21.84 
Vested and released(2,164)$21.31 
Forfeited(1,303)$21.43 
RSUs outstanding at December 31, 2022
11,294 $21.83 1.8 years$181,156 
Activity for PSUs, during the year ended December 31, 2022 was as follows (in thousands, except per share amounts):
Shares
Weighted 
Average
Grant Date
Fair Value
Weighted 
Average
Remaining
Contractual 
Term
Aggregate
Intrinsic
Value
PSUs outstanding at December 31, 2021
6,310 $23.00 
Awarded— $— 
Vested and released(942)$21.32 
Forfeited(404)$24.56 
PSUs outstanding at December 31, 2022
4,964 $23.26 2.3 years$79,628 
Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions
We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the 2022 TSR-based RSUs:
Fair value of Exelixis common stock on grant date
$20.70 
Expected volatility
46.85 %
Risk-free interest rate
1.59 %
Dividend yield
— %
A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:
Fair value of Exelixis common stock on grant date$21.31 
Expected volatility49.21 %
Risk-free interest rate0.29 %
Dividend yield— %